Please login to the form below

Not currently logged in
Email:
Password:

Ironwood Pharmaceuticals appoints chief development officer

Dr Christopher Wright joins from Axcella Health

Ironwood_Pharmaceuticals_Christopher_WrightIronwood Pharmaceuticals has appointed Dr Christopher Wright as its new senior vice president of global development and chief development officer in a role that will see him lead Ironwood’s regulatory, clinical and medical functions and focus on driving the development of its later-stage pipeline candidates.

Mark Currie, chief scientific officer and president of research and development for Ironwood Pharmaceuticals, said: “At this exciting and transformational time for Ironwood, Chris’s collaborative leadership style, dedication to patients and track record of translating science into important therapies for patients will help Ironwood scale our capabilities and enhance the speed, quality functional integration and innovative means by which we advance our medicines to patients”

Prior to joining Ironwood, Wright served in several senior roles such as senior VP and chief medical officer for Axcella Health and senior VP and head of global medicine development and affairs for Vertex Pharmaceuticals.

He said: “With multiple medicines on the market and a rich pipeline advancing through later-stage development, this is an exciting time to join the company, and I look forward to adding my perspective as a physician and scientist to the important work this incredibly talented group of professionals is undertaking.”

10th April 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics